tigatuzumab

mAbexperimental

Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed. — Wikipedia

Clinical trial activity

9 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Apr 28, 2006 (NCT00320827)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cs-1008
  • cs-1008
  • cs-1008
  • cs-1008
  • tigatuzumab
  • tigatuzumab
  • tigatuzumab
  • tra-8

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01307891Phase 2Mar 1, 2011Daiichi Sankyo, Susan G. Komen Breast Cancer Foundation, Triple Negative Breast Cancer Foundation, University of Alabama, Birmingham
NCT01220999Phase 1Oct 1, 2010Austin Health, Daiichi Sankyo, Ludwig Institute for Cancer Research
NCT01124630Phase 1May 1, 2010Daiichi Sankyo
NCT01033240Phase 2Mar 1, 2010Daiichi Sankyo
NCT00945191Phase 2Sep 1, 2009Daiichi Sankyo
NCT00969033Phase 2Jul 1, 2009Daiichi Sankyo
NCT00991796Phase 2Jun 1, 2009Daiichi Sankyo
NCT00521404Phase 2Aug 1, 2007Daiichi Sankyo
NCT00320827Phase 1Apr 28, 2006Daiichi Sankyo
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Daiichi SankyoFor profit9722006
Austin HealthAcademic/Hospital1012010
Ludwig Institute for Cancer ResearchAcademic/Hospital1112010
Susan G. Komen Breast Cancer FoundationAcademic/Hospital1012011
Triple Negative Breast Cancer FoundationAcademic/Hospital1012011
University of Alabama, BirminghamAcademic/Hospital1112011
6 organizations
Page 1 / 1